ALNYAlnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc4,437
Mkt Cap
$40.32BVolume
2.28M52W High
$495.5552W Low
$284.28PE Ratio
71.75ALNY Fundamentals
Price
$301.98Prev Close
$305.06Open
$302.4350D MA
$308.93Beta
0.83Avg. Volume
1.11MEPS (Annual)
$2.33P/B
37.47Rev/Employee
$1.49M$53,617.41
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum PR Newswire NEW YORK, May 28, 2026 USA News Group News CommentaryIssued on behalf ofAva Bio, Inc.As...
PR Newswire
If You Invested $100 In Alnylam Pharmaceuticals Stock 10 Years Ago, You Would Have This Much Today
read more...
Benzinga
Alnylam Issues 2025 Corporate Responsibility Report
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the publication of its 2025 Corporate Responsibility Report. The 2025 report details how the company is scaling its corporate responsibility efforts in tandem with its business growth. Reflected...
Business Wire
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of...
Business Wire
Alnylam to Webcast Presentations at Upcoming Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las...
Business Wire
Bronte Capital Management Pty Ltd. Has $15.45 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY
Bronte Capital Management Pty Ltd. boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.1% in the 4th quarter, according to the company in its most recent filing...
MarketBeat
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type...
Business Wire
PFA Pension Forsikringsaktieselskab Buys Shares of 35,405 Alnylam Pharmaceuticals, Inc. $ALNY
PFA Pension Forsikringsaktieselskab bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 35,405 shares of the biopharmaceutical company's stock, v...
MarketBeat
PKO Investment Management Joint Stock Co Increases Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
PKO Investment Management Joint Stock Co boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 750.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,800 shares of the biopharmaceutical company's stock afte...
MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Kornitzer Capital Management Inc. KS
Kornitzer Capital Management Inc. KS trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 53.1% during the fourth quarter, according to its most recent Form...
MarketBeat
<
1
2
...
>
Compact View
Not available
Not available